Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Merck Sharp & Dohme GesmbH
Woman and Man Max 99 years
Merck Sharp & Dohme GesmbH
Update Il y a 4 ans
A Phase IIb/III Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK-0364 in Obese Patients and in Overweight Patients with Obesity-related Co-morbidities
In obese patients and in overweight patients with obesity-related co-morbidities, to assess the effects of MK-0364 after 1 year of treatment on: 1. body weight; 2. safety and tolerability during tre...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme GesmbH
Update Il y a 4 ans
Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children
Main objective : (1) To evaluate the immunogenicity of intramuscular INFANRIX™ hexa (in relation to serum anti-polyribosylribitol phosphate [PRP] and anti-hepatitis B surface antigen [HBsAg]) when adm...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme GesmbH
Update Il y a 4 ans
A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Monotherapy
Main objective : After 18 weeks, to assess the effect of the addition of treatment with sitagliptin compared to placebo on HbAıc.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Merck Sharp & Dohme GesmbH
Update Il y a 4 ans
A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability, and Efficacy of Aprepitant for the Prevention of Postoperative Nausea and Vomiting (PONV)
1. To demonstrate that aprepitant 40 mg is superior to ondansetron 4 mg IV with respect to the proportion of patients with No Vomiting in the 24 hours following end of surgery. 2. To demonstrate tha...
Country
None
organs
None
Specialty
None
Closed trial
More information